CY1118855T1 - Κρυσταλλικο λεπτοδιαμερισμενο προϊον του βρωμιουχου τιοτροπιου - Google Patents
Κρυσταλλικο λεπτοδιαμερισμενο προϊον του βρωμιουχου τιοτροπιουInfo
- Publication number
- CY1118855T1 CY1118855T1 CY20171100194T CY171100194T CY1118855T1 CY 1118855 T1 CY1118855 T1 CY 1118855T1 CY 20171100194 T CY20171100194 T CY 20171100194T CY 171100194 T CY171100194 T CY 171100194T CY 1118855 T1 CY1118855 T1 CY 1118855T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tiotropi
- brumide
- particle product
- detailed particle
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Medicinal Preparation (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Glass Compositions (AREA)
- Hybrid Cells (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Η εφεύρεση αναφέρεται σε κρυσταλλικό λεπτοδιαμερισμένο προϊόν του βρωμιούχου (1α, 2β, 4β, 5α, 7β)-7-[(υδροξυδι-2-θειενυλακετυλο)οξυ]-9,9-διμεθυλο-3-οξα-9-αζωνιατρικυκλο[3.3.1.02,4]-εννεανίου, σε μέθοδο για την παραγωγή αυτού, καθώς και στη χρήση αυτού για την παραγωγή φαρμακευτικού μέσου, ιδίως για την παραγωγή φαρμακευτικού μέσου με αντιχοληνεργική δράση.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10212264A DE10212264A1 (de) | 2002-03-20 | 2002-03-20 | Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
EP03708206.2A EP1487832B9 (de) | 2002-03-20 | 2003-03-10 | Kristallines mikronisat des tiotropiumbromids |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118855T1 true CY1118855T1 (el) | 2018-01-10 |
Family
ID=27797948
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101300T CY1106923T1 (el) | 2002-03-20 | 2007-10-10 | Κρυσταλλικο λεπτοδιαμερισμενο προϊον του βρωμιουχου τιοτροπιου |
CY20171100194T CY1118855T1 (el) | 2002-03-20 | 2017-02-13 | Κρυσταλλικο λεπτοδιαμερισμενο προϊον του βρωμιουχου τιοτροπιου |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101300T CY1106923T1 (el) | 2002-03-20 | 2007-10-10 | Κρυσταλλικο λεπτοδιαμερισμενο προϊον του βρωμιουχου τιοτροπιου |
Country Status (37)
Country | Link |
---|---|
EP (3) | EP1487832B9 (el) |
JP (1) | JP4331619B2 (el) |
KR (2) | KR101021430B1 (el) |
CN (2) | CN101220025A (el) |
AR (1) | AR039017A1 (el) |
AT (1) | ATE369365T1 (el) |
AU (1) | AU2003212327B2 (el) |
BR (1) | BRPI0308513B8 (el) |
CA (1) | CA2479652C (el) |
CO (1) | CO5611105A2 (el) |
CY (2) | CY1106923T1 (el) |
DE (2) | DE10212264A1 (el) |
DK (2) | DK1487832T4 (el) |
EA (1) | EA007064B1 (el) |
EC (1) | ECSP045310A (el) |
ES (2) | ES2615460T3 (el) |
HK (1) | HK1078871A1 (el) |
HR (1) | HRP20040855B1 (el) |
HU (1) | HUE031876T2 (el) |
IL (2) | IL163841A0 (el) |
LT (1) | LT1785422T (el) |
ME (1) | ME02764B (el) |
MX (1) | MXPA04009056A (el) |
MY (1) | MY139720A (el) |
NO (2) | NO346754B1 (el) |
NZ (1) | NZ535808A (el) |
PE (1) | PE20030838A1 (el) |
PL (1) | PL220730B1 (el) |
PT (2) | PT1785422T (el) |
RS (1) | RS57551B1 (el) |
SA (1) | SA03240098B1 (el) |
SI (1) | SI1487832T2 (el) |
TW (1) | TWI345975B (el) |
UA (1) | UA78295C2 (el) |
UY (1) | UY27725A1 (el) |
WO (1) | WO2003078429A1 (el) |
ZA (1) | ZA200405636B (el) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
DK1682543T3 (da) | 2003-11-03 | 2010-12-13 | Boehringer Ingelheim Int | Fremgangsmåde til fremstilling af nye tiotropiumsalte |
DE502004010885D1 (de) | 2003-11-03 | 2010-04-22 | Boehringer Ingelheim Pharma | Verfahren zur herstellung von tiotropiumsalzen |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
DE102004024451A1 (de) | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
CA2606552A1 (en) * | 2005-05-02 | 2006-11-09 | Boehringer Ingelheim International Gmbh | Crystalline forms of tiotropium bromide |
BRPI0609295A2 (pt) | 2005-05-02 | 2010-03-23 | Boehringer Ingelheim Int | formas cristalinas de brometo de tiotràpio, composiÇço farmacÊutica, uso e mÉtodo para preparar as mesmas |
PL1917253T3 (pl) | 2005-08-15 | 2015-06-30 | Boehringer Ingelheim Int | Sposób wytwarzania betamimetyków |
US20070086957A1 (en) * | 2005-10-10 | 2007-04-19 | Thierry Bouyssou | Combination of medicaments for the treatment of respiratory diseases |
DE102005059602A1 (de) * | 2005-12-14 | 2007-06-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Mikronisierung |
JP5086267B2 (ja) | 2005-12-19 | 2012-11-28 | シコール インコーポレイティド | 臭化チオトロピウムの新規な形態およびそれを製造する方法 |
US9108962B2 (en) | 2005-12-19 | 2015-08-18 | Sicor, Inc. | Forms of tiotropium bromide and processes for preparation thereof |
CN100999521B (zh) * | 2006-01-13 | 2010-12-08 | 江苏正大天晴药业股份有限公司 | 结晶性抗胆碱药噻托溴铵 |
GB0716026D0 (en) | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
WO2011093815A2 (en) * | 2010-01-29 | 2011-08-04 | Mahmut Bilgic | Pharmaceutical compositions comprising formoterol and mometasone |
GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
PT106142B (pt) * | 2012-02-10 | 2014-07-18 | Hovione Farmaci Ncia S A | Processo para a preparação de brometo de tiotrópio |
WO2014007768A1 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhaler compositions comprising long acting muscorinic antagonists |
EP2705838A1 (en) * | 2012-09-06 | 2014-03-12 | Xspray Microparticles Ab | Tiotropium preparations |
WO2014042605A1 (en) * | 2012-09-11 | 2014-03-20 | Mahmut Bilgic | New tiotropium bromide crystalline form |
US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
SI3191081T1 (sl) | 2014-09-09 | 2020-07-31 | Vectura Limited | Formulacija, ki vsebuje glikopirolat, postopek in naprava |
WO2017068119A1 (en) * | 2015-10-23 | 2017-04-27 | Arven Ilac Sanayi Ve Ticaret A.S. | Blister for tiotropium bromide inhalable formulation |
BR112018008083A2 (pt) * | 2015-10-23 | 2018-10-23 | Arven Ilac Sanayi Ve Ticaret As | blister para formulação inalável de brometo de tiotrópio |
CN115737610B (zh) * | 2021-12-13 | 2024-02-27 | 苏州欧米尼医药有限公司 | 一种噻托溴铵吸入粉雾剂及其活性成分的气流粉碎方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
IE59026B1 (en) | 1985-07-30 | 1993-12-15 | Glaxo Group Ltd | Devices for administering medicaments to patients |
US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
DE4318455A1 (de) | 1993-06-03 | 1994-12-08 | Boehringer Ingelheim Kg | Kapselhalterung |
DE19515625C2 (de) * | 1995-04-28 | 1998-02-19 | Boehringer Ingelheim Kg | Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern |
FR2779347A1 (fr) * | 1998-06-05 | 1999-12-03 | Arlette Guerry | Procede de micronisation de substances medicamenteuses |
ES2193726T3 (es) | 1998-08-04 | 2003-11-01 | Jago Res Ag | Formulaciones de aerosol medicinales. |
RO122660B1 (ro) * | 1998-11-13 | 2009-11-30 | Skypepharma Ag | Pulbere inhalabilă uscată |
GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
JP2002542297A (ja) † | 1999-04-23 | 2002-12-10 | リサーチ コーポレイション テクノロジーズ,インコーポレイテッド | 血管形成を増強するための治療組成物および方法 |
CA2387212A1 (en) | 1999-10-12 | 2001-04-19 | Kaken Pharmaceutical Co., Ltd. | Dry powder inhalation and a method for the preparation thereof |
OA12522A (en) | 2000-10-12 | 2006-05-30 | Boehringer Ingelheim Pharma | Novel tiotropium-containing inhalation powder. |
EP1468998A1 (de) | 2000-10-12 | 2004-10-20 | Boehringer Ingelheim Pharma GmbH & Co. KG | Kristallines Monohydrat von Tiotropiumbromid und Verfahren zu dessen Herstellung. |
DE10126924A1 (de) | 2001-06-01 | 2002-12-05 | Boehringer Ingelheim Pharma | Inhalationskapseln |
CN100586948C (zh) | 2001-06-22 | 2010-02-03 | 贝林格尔英格海姆法玛两合公司 | 结晶性抗胆碱能药,其制备方法及其在药物制备中的用途 |
US7309707B2 (en) | 2002-03-20 | 2007-12-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
AU2003276525A1 (en) | 2002-11-15 | 2004-06-15 | Orchid Chemicals And Pharmaceuticals Ltd | Novel amorphous hydrate of a cephalosporin antibiotic |
DE102005059602A1 (de) | 2005-12-14 | 2007-06-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Mikronisierung |
CN102127069A (zh) | 2010-01-20 | 2011-07-20 | 鲁南制药集团股份有限公司 | 噻托溴铵晶体 |
-
2002
- 2002-03-20 DE DE10212264A patent/DE10212264A1/de not_active Withdrawn
-
2003
- 2003-03-10 KR KR1020047014831A patent/KR101021430B1/ko active IP Right Grant
- 2003-03-10 ME MEP-2008-467A patent/ME02764B/me unknown
- 2003-03-10 AT AT03708206T patent/ATE369365T1/de active
- 2003-03-10 ES ES07102206.5T patent/ES2615460T3/es not_active Expired - Lifetime
- 2003-03-10 ES ES03708206.2T patent/ES2291619T5/es not_active Expired - Lifetime
- 2003-03-10 BR BRPI0308513A patent/BRPI0308513B8/pt not_active IP Right Cessation
- 2003-03-10 DE DE50307883T patent/DE50307883D1/de not_active Expired - Lifetime
- 2003-03-10 PL PL371799A patent/PL220730B1/pl unknown
- 2003-03-10 RS RS82604A patent/RS57551B1/sr unknown
- 2003-03-10 MX MXPA04009056A patent/MXPA04009056A/es active IP Right Grant
- 2003-03-10 EP EP03708206.2A patent/EP1487832B9/de not_active Expired - Lifetime
- 2003-03-10 PT PT71022065T patent/PT1785422T/pt unknown
- 2003-03-10 AU AU2003212327A patent/AU2003212327B2/en not_active Expired
- 2003-03-10 CN CNA2008100024354A patent/CN101220025A/zh active Pending
- 2003-03-10 IL IL16384103A patent/IL163841A0/xx unknown
- 2003-03-10 DK DK03708206.2T patent/DK1487832T4/en active
- 2003-03-10 LT LTEP07102206.5T patent/LT1785422T/lt unknown
- 2003-03-10 KR KR1020107028543A patent/KR101094091B1/ko active IP Right Grant
- 2003-03-10 EP EP16159836.2A patent/EP3053921A1/de not_active Withdrawn
- 2003-03-10 CN CNB038065169A patent/CN100368410C/zh not_active Ceased
- 2003-03-10 SI SI200330973T patent/SI1487832T2/sl unknown
- 2003-03-10 HU HUE07102206A patent/HUE031876T2/en unknown
- 2003-03-10 PT PT03708206T patent/PT1487832E/pt unknown
- 2003-03-10 DK DK07102206.5T patent/DK1785422T3/en active
- 2003-03-10 EP EP07102206.5A patent/EP1785422B1/de not_active Expired - Lifetime
- 2003-03-10 WO PCT/EP2003/002422 patent/WO2003078429A1/de active IP Right Grant
- 2003-03-10 EA EA200401142A patent/EA007064B1/ru not_active IP Right Cessation
- 2003-03-10 JP JP2003576434A patent/JP4331619B2/ja not_active Expired - Lifetime
- 2003-03-10 NZ NZ535808A patent/NZ535808A/en not_active IP Right Cessation
- 2003-03-10 CA CA2479652A patent/CA2479652C/en not_active Expired - Fee Related
- 2003-03-10 NO NO20190824A patent/NO346754B1/no not_active IP Right Cessation
- 2003-03-18 MY MYPI20030947A patent/MY139720A/en unknown
- 2003-03-18 PE PE2003000268A patent/PE20030838A1/es not_active Application Discontinuation
- 2003-03-18 UY UY27725A patent/UY27725A1/es not_active Application Discontinuation
- 2003-03-18 TW TW092105919A patent/TWI345975B/zh not_active IP Right Cessation
- 2003-03-19 AR ARP030100957A patent/AR039017A1/es not_active Suspension/Interruption
- 2003-04-29 SA SA03240098A patent/SA03240098B1/ar unknown
- 2003-10-03 UA UA20041008391A patent/UA78295C2/uk unknown
-
2004
- 2004-07-15 ZA ZA2004/05636A patent/ZA200405636B/en unknown
- 2004-08-31 IL IL163841A patent/IL163841A/en not_active IP Right Cessation
- 2004-09-17 HR HR20040855 patent/HRP20040855B1/xx not_active IP Right Cessation
- 2004-09-23 EC EC2004005310A patent/ECSP045310A/es unknown
- 2004-09-23 NO NO20044003A patent/NO344427B1/no not_active IP Right Cessation
- 2004-10-15 CO CO04104123A patent/CO5611105A2/es not_active Application Discontinuation
-
2005
- 2005-12-01 HK HK05110949A patent/HK1078871A1/xx not_active IP Right Cessation
-
2007
- 2007-10-10 CY CY20071101300T patent/CY1106923T1/el unknown
-
2017
- 2017-02-13 CY CY20171100194T patent/CY1118855T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118855T1 (el) | Κρυσταλλικο λεπτοδιαμερισμενο προϊον του βρωμιουχου τιοτροπιου | |
CY1105223T1 (el) | Κρυσταλλικο αντιχολινepγικο, μεθοδος για την παραγωγη του και τη χρηση του για τη παραγωγη ενος φαρμακου | |
ME00243B (me) | Kristalni monohidrat, postupak za njegovo pripremanje i njegova primena za pripremanje lijeka | |
WO2002072095A3 (de) | Tiotropiumsalzen zur behandlung von inflammatorischen erkrankungen | |
EA200300666A1 (ru) | Способ получения обладающего антихолинергическим действием тиотропийбромида | |
MEP36608A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
NO2013017I1 (no) | (a)dekstrometorfan eller et farmasøytisk akseptabelt salt, en forløper eller derivat, for eksempel ekstrometorfanhydrobromid og spesielt dekstrometorfanhydrobromid monohydrat; og (b) quinidin eller etfarmasøytisk akseptabelt salt, en forløper eller derivat derav, for eksempel quinidin og spesielt quinidinsulfat dihydrat | |
DE60325354D1 (de) | Topisch anwendbare pharmazeutische zubereitung | |
ES2164097T3 (es) | Uso de anestesicos topicos para la fabricacion de un medicamento para el tratamiento del asma bronquial. | |
DE68913132D1 (de) | Hirudin und Aktivator des Plasminogens enthaltende pharmazeutische wirksame Verbindung. | |
CY1111355T1 (el) | Μειωση της ζαλης, μια παρενεργεια που συσχετιζεται με την θεραπεια πιρφενιδονης | |
IT8947875A0 (it) | Derivati di acido piridoncarbossilico e loro sali, procedimento per produrre gli stessi e agenti antibatterici che li contengono | |
BRPI0517416A (pt) | inibidores de pi3 quinase gama para o tratamento de anemia | |
SE0104423D0 (sv) | Pregnane steroids and their use in the treatment of CNS disorders | |
ATE33253T1 (de) | Verfahren zur herstellung von reinen dermatansulfat- und herapansulfatglykosaminoglukanen und ihre pharmazeutische verwendung. | |
MY137249A (en) | Aerosol formulation for inhalation containing a tiotropium salt | |
Iwatsuki et al. | Biochemical and Pharmacological Profiles of YM150, an Oral Direct Factor Xa Inhibitor. | |
EA200401190A1 (ru) | Суспензионные препараты с пропеллентом hfa, содержащие антихолинергическое средство | |
AR035553A1 (es) | Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos. | |
MEP47308A (en) | Hfa-suspension formulation of an anhydrate | |
FI954614A (fi) | Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina | |
AU7690891A (en) | Use of platelet activating factor antagonists as anti-pruritic agents | |
CA2105888A1 (fr) | Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un medicament a activite thrombolytique | |
Lowell | Growing interest in thalidomide | |
ECSP034921A (es) | Anticolinérgico cristalino, metodo para su producción, y uso del mismo en la producción de una droga |